## Carolina Vicente-Dueñas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4981947/publications.pdf

Version: 2024-02-01

279798 233421 2,246 63 23 45 citations g-index h-index papers 63 63 63 3841 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice. Cancer Research, 2022, 82, 1098-1109.	0.9	9
2	Childhood B-Cell Preleukemia Mouse Modeling. International Journal of Molecular Sciences, 2022, 23, 7562.	4.1	2
3	Conditional expression of HGAL leads to the development of diffuse large B-cell lymphoma in mice. Blood, 2021, 137, 1741-1753.	1.4	6
4	Infectious triggers and novel therapeutic opportunities in childhood B cell leukaemia. Nature Reviews Immunology, 2021, 21, 570-581.	22.7	25
5	An immune window of opportunity to prevent childhood B cell leukemia. Trends in Immunology, 2021, 42, 371-374.	6.8	8
6	The Second Oncogenic Hit Determines the Cell Fate of ETV6-RUNX1 Positive Leukemia. Frontiers in Cell and Developmental Biology, 2021, 9, 704591.	3.7	19
7	In Vivo Generation of Leukemic Stem Cells by HSC Targeting by Transgenesis. Methods in Molecular Biology, 2021, 2185, 361-372.	0.9	0
8	Cell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia. Blood Cancer Discovery, 2020, 1, 224-233.	5.0	17
9	An intact gut microbiome protects genetically predisposed mice against leukemia. Blood, 2020, 136, 2003-2017.	1.4	64
10	Inhibition of inflammatory signaling in Pax5 mutant cells mitigates B-cell leukemogenesis. Scientific Reports, 2020, 10, 19189.	3.3	15
11	Editorial: Epigenetic Reprogramming and Cancer Development. Frontiers in Cell and Developmental Biology, 2020, 8, 12.	3.7	1
12	Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia. Leukemia, 2019, 33, 249-278.	7.2	18
13	Epigenetic Priming in Childhood Acute Lymphoblastic Leukemia. Frontiers in Cell and Developmental Biology, 2019, 7, 137.	3.7	9
14	Novel <i>ETV6â€RUNX1</i> Mouse Model to Study the Role of ELFâ€MF in Childhood Bâ€Acute Lymphoblastic Leukemia: a Pilot Study. Bioelectromagnetics, 2019, 40, 343-353.	1.6	12
15	Infectious stimuli promote malignant B-cell acute lymphoblastic leukemia in the absence of AID. Nature Communications, 2019, 10, 5563.	12.8	21
16	Loss of Pax5 Exploits Sca1-BCR-ABLp190 Susceptibility to Confer the Metabolic Shift Essential for pB-ALL. Cancer Research, 2018, 78, 2669-2679.	0.9	37
17	Lineage choice decisions in B-cell development and leukemia. Stem Cell Investigation, 2018, 5, 46-46.	3.0	0
18	Epigenetic Priming in Cancer Initiation. Trends in Cancer, 2018, 4, 408-417.	7.4	81

#	Article	IF	Citations
19	The Making of Leukemia. International Journal of Molecular Sciences, 2018, 19, 1494.	4.1	12
20	T-cell leukemogenesis is an inappropriate lineage decision-making process: implications for precision oncology. Molecular and Cellular Oncology, 2018, 5, e1497860.	0.7	1
21	Lmo2 expression defines tumor cell identity during Tâ€cell leukemogenesis. EMBO Journal, 2018, 37, .	7.8	32
22	A Tumor Suppressor Role for Bank1 in B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2018, 132, 1333-1333.	1.4	0
23	Infection Exposure Promotes <i>ETV6-RUNX1</i> Precursor B-cell Leukemia via Impaired H3K4 Demethylases. Cancer Research, 2017, 77, 4365-4377.	0.9	76
24	Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice. Blood, 2017, 129, 2645-2656.	1.4	84
25	Activation-induced cytidine deaminase prevents pro-B cell acute lymphoblastic leukemia by functioning as a negative regulator in Rag1 deficient pro-B cells. Oncotarget, 2017, 8, 75797-75807.	1.8	4
26	Modeling the process of childhood <i>ETV6-RUNX1</i> B-cell leukemias. Oncotarget, 2017, 8, 102674-102680.	1.8	8
27	MAFB (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog B). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017, , .	0.1	O
28	Could Vitamin D Analogues Be Used to Target Leukemia Stem Cells?. International Journal of Molecular Sciences, 2016, 17, 889.	4.1	2
29	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 207-217.	7.0	21
30	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1116-25.	7.1	307
31	Infection Exposure Is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of <i>Pax5</i> Inherited Susceptibility. Cancer Discovery, 2015, 5, 1328-1343.	9.4	117
32	Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy. Seminars in Cancer Biology, 2015, 32, 3-9.	9.6	22
33	A New ETV6-RUNX1 In Vivo Model Produces a Phenocopy of the Human Pb-ALL. Blood, 2015, 126, 3658-3658.	1.4	O
34	Early epigenetic cancer decisions. Biological Chemistry, 2014, 395, 1315-1320.	2.5	7
35	Identification of cancer initiating cells in <i>K-Ras</i> driven lung adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 255-260.	7.1	151
36	Hit-and-run lymphomagenesis by theBcl6oncogene. Cell Cycle, 2014, 13, 1831-1832.	2.6	6

#	Article	IF	CITATIONS
37	Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis. Cell Cycle, 2014, 13, 1717-1726.	2.6	7
38	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature Communications, 2014, 5, 3904.	12.8	73
39	Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma. Blood, 2014, 124, 2001-2001.	1.4	2
40	p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. Cell Cycle, 2013, 12, 122-132.	2.6	16
41	Function of oncogenes in cancer development: a changing paradigm. EMBO Journal, 2013, 32, 1502-1513.	7.8	84
42	Cancer Stem Cells and Modeling Cancer in the Mouse. , 2013, , 227-234.		0
43	Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nature Communications, 2013, 4, 1338.	12.8	37
44	Genetic background affects susceptibility to tumoral stem cell reprogramming. Cell Cycle, 2013, 12, 2505-2509.	2.6	3
45	A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO Journal, 2012, 31, 3704-3717.	7.8	62
46	Understanding telomerase in cancer stem cell biology. Cell Cycle, 2012, 11, 1479-1480.	2.6	9
47	MALT lymphoma meets stem cells. Cell Cycle, 2012, 11, 2961-2962.	2.6	7
48	The cellular architecture of multiple myeloma. Cell Cycle, 2012, 11, 3715-3717.	2.6	12
49	Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by <i><i>MafB</i></i> Cell Cycle, 2012, 11, 3896-3900.	2.6	23
50	Expression of <i>MALT1</i> oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 10534-10539.	7.1	73
51	Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice. Oncotarget, 2012, 3, 261-266.	1.8	23
52	HGAL-a Germinal Center Specific Protein, Enhances B-Cell Receptor Signaling by Activation of Syk, Leading to Follicular Lymphoproliferation. Blood, 2011, 118, 584-584.	1.4	1
53	Cancer as a reprogramming-like disease: Implications in tumor development and treatment. Seminars in Cancer Biology, 2010, 20, 93-97.	9.6	39
54	Bcl2 is not required for the development and maintenance of leukemia stem cells in mice. Carcinogenesis, 2010, 31, 1292-1297.	2.8	8

#	Article	lF	CITATIONS
55	The evolution of cancer modeling: the shadow of stem cells. DMM Disease Models and Mechanisms, 2010, 3, 149-155.	2.4	15
56	The age of the target cell affects B-cell leukaemia malignancy. Aging, 2010, 2, 908-913.	3.1	14
57	Stem-cell driven cancer: "Hands-off" regulation of cancer development. Cell Cycle, 2009, 8, 1314-1318.	2.6	36
58	Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO Journal, 2009, 28, 8-20.	7.8	125
59	The Role of Cellular Plasticity in Cancer Development. Current Medicinal Chemistry, 2009, 16, 3676-3685.	2.4	39
60	Fat-specific FUS-DDIT3-transgenic mice establish PPARÂ inactivation is required to liposarcoma development. Carcinogenesis, 2007, 28, 2069-2073.	2.8	15
61	Snail Family Transcription Factors Are Implicated in Thyroid Carcinogenesis. American Journal of Pathology, 2007, 171, 1037-1046.	3.8	78
62	Function of the Zinc-Finger Transcription FactorSNAI2in Cancer and Development. Annual Review of Genetics, 2007, 41, 41-61.	7.6	170
63	The theoretical basis of cancerâ€stemâ€eellâ€based therapeutics of cancer: can it be put into practice?. BioEssays, 2007, 29, 1269-1280.	2.5	81